REVVITY, INC. (RVTY)
NYSE · Instruments & Medical Devices · Laboratory Analytical Instruments
- Price
- $142.11
- Day
- -0.84%
- Market cap
- $15.86B
- P/E
- 66.8
Close 2026-09-23.
The company
Overview We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index. We maintain a website with the address http://www.revvity.com . We are not including the information contained in our website as part of, or incorporating it by reference into, this annual report on Form 10-K. We make available free of charge through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports, as soon as reasonably practicable after we electronically file these materials with, or otherwise furnish them to, the Securities and Exchange Commission.
From Item 1: Overview.
By product & service
- Product — 84%
- Service — 16%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- EdgePoint Investment Group Inc. — $950.66M
- Jupiter Topco LLC — $901.56M
- VANGUARD CAPITAL MANAGEMENT LLC — $812.31M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $530.76M
- STATE STREET CORP — $483.17M
- BlackRock, Inc. — $390.15M
- VICTORY CAPITAL MANAGEMENT INC — $384.36M
- DIMENSIONAL FUND ADVISORS LP — $363.15M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Vohra Tajinder S (Please See Remarks) sold 7,330 shares at $140.88 on 2026-09-16
- Gonzales Anita (Vice President and CAO) sold 85 shares at $109.48 on 2026-07-20
- Gonzales Anita (Vice President and CAO) sold 80 shares at $92.80 on 2026-04-20
- Victor Miriame (Please See Remarks) sold 1,862 shares at $97.13 on 2026-02-24
- McMurry-Heath Michelle (Director) sold 600 shares at $97.26 on 2026-02-23
- Singh Prahlad R. (Please See Remarks) sold 7,885 shares at $100.63 on 2026-02-05
Recent filings
- 144 — 2026-09-21
- 4 — 2026-09-18
- 144 — 2026-09-16
- SCHEDULE 13G/A — 2026-09-08
- 4 — 2026-08-25
- 4 — 2026-08-18
- 4 — 2026-08-17
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- 10-Q — 2026-08-11